Immix Biopharma | Investor Presentation Deck | 46 slides · page 26 of 46
Layout splits into three quadrants of charts (survival %, tumor response %, median survival days) plus a navy summary band; Immix Biopharma logo top-right and page number 26 bottom-right.
Pitch deck · traction · show_traction · overcrowded density
Slide locked Sign in to view
Slide schematic 14/14
callout 1/1 chart 3/3 image 1/1 list 3/3 source-note 2/2 title 4/4
Components 14
primary bar-vertical bar-vertical bar-vertical logo bullet bullet bullet source-note source-note headline subtitle subtitle subtitle
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 3
Action Titles 75%
Section headers and the navy summary band state the takeaway, not just the topic.
Peer gap chart 70%Bar charts contrast IMX-110 against Trabectedin standard-of-care and a 4-drug combination benchmark.
Quantification 80%Headline numbers (75% vs 0%, -41% vs +23%, 63 vs 42 days) anchor each claim.